In a biotech world dominated by giants and billion-dollar R&D budgets, Prevencio Med is quietly building a weapon against the world's #1 killer. With just 13 employees and $2M in revenue, they're not playing the traditional game—they're rewriting the rules of cardiac diagnostics.

"They aren't building yet another diagnostic platform—they're building the diagnostic platform that actually gets used."

The leadership team reads like a dream team for commercialization: Rhonda Rhyne wears multiple hats (CEO, President, CTO, Board Director), suggesting tight control and vision. Missy Kemp as CCO brings commercial firepower, Grady Barnes as CSO anchors the science, and Craig Magaret as CAO ensures data-driven decisions. This isn't a science project—it's a commercial machine wearing a biotech cloak.

• Lean execution: 13 people generating $2M = $154K revenue per employee
• Clinical depth: 7 distinct cardiac tests suggests IP moat and platform thinking
• Modern stack: Tailwind + HubSpot + Google Analytics shows they're digitally native
• Social presence: Active across 5 platforms indicates they understand modern B2B2C marketing